Bivalirudin in Patient at High Risk of Bleeding Undergoing Percutaneous Coronary Interventions.
Phase of Trial: Phase III
Latest Information Update: 11 Mar 2015
At a glance
- Drugs Bivalirudin (Primary) ; Heparin
- Indications Cardiovascular disorders; Thromboembolism
- Focus Adverse reactions
- Acronyms NAPLES-III
- 31 Aug 2018 Biomarkers information updated
- 11 Mar 2015 Trial design presented at Cardiovascular Drugs and Therapy.
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.